Michael Loney rounds up Patent Trial and Appeal Board-related decisions of note in January, including a precedential Federal Circuit decision on standing to appeal in Phigenix v ImmunoGen and two district court estoppel decisions
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
Daniel Tarr explains why returning to his former firm could help him establish his personal brand, and predicts what’s on the horizon for AI litigation
A call to reinstate the European Commission's controversial SEP proposal and a trademark row involving Stanley cups were also among the top talking points